If you forgot to drink femoston. How to drink femoston and its possible side effects. Femoston when planning pregnancy: side effects

Femoston belongs to the list of drugs with combined action used in the case of replacement therapy during menopause. Instructions for use, price, analogues, reviews of women about its effectiveness will be described below. As the main active substance of this drug, estradiol is used - corresponding to natural sex hormones and dydrogesterone, which is a gestagenic component.

Form of the drug

Femoston is a drug produced in three forms, each is a pack of 28 tablets. These varieties are due only to the number of components and are available only in the form of tablets for internal use. Each form contains a certain dose of the active substance, namely:

• Femoston 1/5 tablet contains: estradiol - 1 mg, dydrogesterone - 5 mg;
• white tablets Femoston 1/10 contain: estradiol - 1 mg;
• Femoston 1/10 gray tablets contain: estradiol - 1 mg, dydrogesterone - 10 mg;
• Femoston 2/10 pink tablets contain: estradiol - 2 mg;
• Femoston 2/10 light yellow tablets contain: estradiol - 2 mg, dydrogesterone - 10 mg.

In addition, it contains various excipients in the form of lactose monohydrate, starch, magnesium stearate, methylhydroxypropyl cellulose, macrogol 400, iron oxide, Opadry of different colors.

Drug properties

Thanks to estradiol, Femoston provides a sufficient level of estrogen in women, which begins to decline rapidly during menopause. Thanks to this, the autonomic system and the negative symptoms of menopause return to normal, and the frequency of hot flashes, increased sweating, headache attacks, dizziness, and swelling become rarer or disappear altogether.

Estradiol contributes to the cyclic changes that occur in the vagina, in the uterus and in its neck, and also to maintain the elasticity of the urinary tract. The content of estradiol allows Femoston to have a preventive effect against osteoporosis and preserve bone tissue. The presence of dydrogesterone also plays an important role, due to the fact that a sufficient amount of it controls the secretion phase of the endometrium, reduces the possibility of its hyperplasia.

Indications for the use of Femoston

The drug is used with a lack of hormones as a replacement therapy for disorders of the reproductive system resulting from an operation on the genitals (most often after removal of the ovaries) or during menopause. Also, its use is shown as a preventive method against the development of osteoporosis. The drug Femoston is able to make up for the insufficient amount of sex hormones in a woman's body, the level of which decreases during menopause, thereby helping to maintain the normal functioning of all organs. Therefore, it is prescribed in the event of various pathological conditions due to the created deficiency of sex hormones.
Since there are several varieties of the drug with the same therapeutic properties, different dosages of the main components allow you to choose exactly the form that is most suitable for a woman.

The use of Femoston for all its forms is the same - to eliminate the pathological manifestations of menopause, manifested in the form of annoying hot flashes, insomnia, unreasonable emotional excitability, dryness and discomfort in the vagina, that is, everything that is caused by an insufficient amount of estrogen.

The use of Femoston

The drug 1/5 is prescribed if the postmenopause in patients lasts more than a year. The dose of the drug is 1 tablet per day and at the same hours.

Femoston 1/10 is recommended to take 1 tablet every day at a certain hour. For 2 weeks, white tablets from a package marked with a unit are used. In the next two weeks, take 1 gray tablet from the second blister.

The same applies to Femoston 2/10: for the first 2 weeks, one orange tablet is used, after which, for the remaining time, yellow tablets are taken.

Women who have preserved menstrual functions should begin treatment with Femoston from the beginning of menstruation. Those who have an irregular cycle should start using this drug only after two weeks of monotherapy using a progestogen belonging to the group of steroid sex hormones. The main purpose of this method is to regulate the sexual cycle.

Women who do not have periods for a year or more can start using Femoston at a convenient time for her.

If the next pill is missed, and the delay period does not exceed 12 hours, then the missed pill can be taken without fear. If this period exceeds 12 hours, then it is thrown out of the package, and the next day the drug is taken according to the schedule. Under no circumstances should two tablets be used together.

The drug can be used for a long time and is suitable for use for several years.

Side effect

While taking Femoston, some undesirable effects may occur, therefore, in the first days of using the drug, it is necessary to analyze your feelings more carefully. There may be headaches and migraine attacks, nausea, sensations of cramps in the legs, the appearance of bloody discharge from the vagina, increased sensitivity of the mammary glands, weight changes and asthenia.

Not necessarily, but vaginal candidiasis, violations of sexual desire, development of edema, skin allergies, exacerbation of chronic pathologies, changes in secretion from the cervical canal can manifest themselves.

Hemolytic jaundice, chorea may also develop, the risk of stroke, heart attack, vascular purpura, melasma and chloasma may increase, which may not immediately disappear even after discontinuation of the drug. Therefore, with severe pathological disorders in the past, patients are required to be examined by specialists every three months.

When using Femoston, it is necessary to evaluate the risk of taking the drug and the beneficial results obtained from treatment at least once a year. Based on this assessment, a decision is made on the advisability of further use, as well as on the rejection of methods with hormone replacement therapy.

Contraindications

The ban on the use of Femoston is the identification of benign neoplasms in the internal genital organs, or the formation of nodes and seals in the mammary gland. It is contraindicated to use Femoston in conditions such as:

The use of the drug should be discontinued if migraine occurs, manifestations of jaundice due to poor liver condition, during pregnancy, a strong rise in blood pressure. Cancellation of Femoston during exacerbation of these conditions is carried out with the consent of the doctor.

Existing analogues

Femoston has no analogues with similar dosages of active substances, however, there are a number of drugs that are similar in therapeutic actions. They also have anti-menopausal properties based on estrogen and progesterone, namely: Activel, Angelica, Divitren, Indivina, Klimen, Kliogest, Pauzogest, Triaclima and others tablets, as well as Gynodian Depot or Cyclo-Proginov injections in the form of dragees. All of them also contribute to maintaining normal hormonal levels and have the most beneficial effect on the body.

It may happen earlier. For early and standard menopause, the same manifestations are characteristic, which are expressed in a violation of the menstrual cycle, and sometimes in the complete absence of discharge. In addition, women experience psycho-emotional disorders, manifested in excessive irritability and insomnia along with excessive fatigue. With such unpleasant manifestations, various means help to fight. One of the excellent solutions in alleviating menopause can be a complex treatment with Femoston 2/10.

Reviews about it will be considered in this article.

Tool description

As you know, with the onset of menopause, the formation of the main hormones, especially estrogen, is significantly reduced. Artificial introduction into the body of the missing amount of such hormones comes to the rescue in order to stabilize the background. At each stage of menopause, whether it is menopause or postmenopause, the level of hormones is completely different.

"Femoston 2/10" is the most common representative of drugs that are used for menopause. It contains synthetic hormones that fully simulate the action of natural components. Given that with the advent of menopause, first of all, the psycho-emotional system suffers, this drug eliminates such manifestations. Thus, thanks to him, absent-mindedness and sudden mood swings are eliminated along with stress, unreasonable sadness, irritability, apathy, increased fatigue and insomnia. This is confirmed by the instructions and reviews for Femoston 2/10.

Hormonal surges send false signals to the pituitary gland, which is responsible for thermoregulation, as a result of which women can suffer from hot flashes up to thirty times a day. Chills with increased sweating appear more often. Violation in the work of the genital organs manifests itself in the form of pain and a decrease in libido. Calcium is especially deficient during such a period, due to which the bone tissues become significantly thinner, pain and cramps occur in the limbs. It is not uncommon for the appearance of pulling pains in the lumbar region, and the development of osteochondrosis is also possible. The skin also suffers, losing its elasticity, forming wrinkles. No less than the rest, the heart and blood vessels suffer, making themselves felt by headaches, as well as jumps in blood pressure. The tool "Femoston 2/10" helps to cope with absolutely all of the listed symptoms.

In addition to the fact that the drug fights the symptoms of menopause, this drug has a beneficial effect on the thickening of the endometrium. With early menopause, this makes it possible to induce ovulation, increasing the chances of pregnancy.

Reviews about "Femoston 2/10" are of interest to many.

Compound

The drug is a combined hormonal agent with a biphasic effect. Its main active substances are beta-estradiol in combination with dydrogesterone. The action of the first component is identical to the functions of natural estradiol, the second is similar to the effects of progesterone.

The estrogen element replenishes the supply of estrogen in a woman's body, allowing you to restore the balance of the psycho-emotional system and stop the autonomic symptoms of menopause. At the postmenopausal stage, this substance prevents the deterioration of bone mass. The gestagenic substance promotes the natural flow of secretion in the endometrium and thereby eliminates the development of neoplasms, preventing the occurrence of certain hormone-dependent diseases. According to reviews, "Femoston 2/10" is very effective in planning. More on this later.

Mechanism of action

In mutual combination, these substances help to effectively eliminate the symptoms of menopause, stabilizing metabolism and lowering cholesterol levels. To a certain extent, they help to rejuvenate the entire female body, not only from the inside, but also from the outside.

Experts say that estradiol, as well as dydrogesterone, is rapidly absorbed when ingested. Both components are excreted in the urine after seventy hours. The excipients in this preparation are corn starch, magnesium stearate, and silicon dioxide along with lactose monohydrate.

According to reviews, the instructions for Femoston 2/10 are very detailed.

Contraindications for the use of the drug

Given that this remedy is hormonal, it has a wide range of different contraindications, which include the following conditions:

• The presence of individual intolerance to any components included in the composition of the drug.
• The state of pregnancy, as well as the period of feeding the baby.
• The development of breast cancer or suspicion of it.
• Neoplasms that depend on estrogen, or suspicion of such.
• Presence of endometrial hyperplasia.
• The presence of vaginal or uterine bleeding of unknown origin.
• Any pathology of the liver.
• Kidney disease and adrenal insufficiency.
• Porphyria along with venous thromboembolism, or suspicion of it.
• The presence of arterial thromboembolism.

special care

With extreme caution, this drug should be used by diabetics, and, in addition, people who suffer from heart and vascular ailments. Before using the remedy, it is required to undergo an extensive examination, as well as take into account the possible risks of the appearance of hereditary diseases.

Side effects

According to reviews, "Femoston 2/10" can cause a large number of side effects. For example, the following unpleasant consequences can be observed:

• The occurrence of breakthrough bleeding.

• The appearance of pain in the pelvic area and mammary glands along with their increase.
• Erosive pathologies in the cervix.
• Problems in sexual life.
• Disruptions of the digestive system in the form of vomiting, nausea, diarrhea and flatulence.
• The appearance of dizziness.
• Allergic reactions in the form of itching, various rashes and redness.

In addition, it should be noted that as part of taking this drug, weight gain and vaginal candidiasis may occur. This is confirmed by numerous reviews.

"Femoston 2/10" when planning pregnancy can also be prescribed.

Pregnancy planning

Doctors use the drug to solve problems that prevent a woman from becoming pregnant. This is insufficient estrogen production and a thin endometrium. Thanks to the dydrogesterone, which is part of the composition, the secretion phase begins faster. All this contributes to the thickening and growth of the uterine mucosa, which is required for easy attachment of a fertilized egg. The drug restores ovulation, although it occurs only after the drug is discontinued.

Reviews about "Femoston 2/10"

The drug is distinguished by the presence of rather conflicting reviews, both doctors and patients. Many talk about the effectiveness of this remedy at any stage of menopause, while others are completely opposed to hormone therapy. Nevertheless, most reviews on the Internet report a positive effect of the presented remedy on the woman's body. This is confirmed by the instructions for use.

Reviews about "Femoston 2/10" from doctors

All doctors' opinions are similar in that women's health requires support at any age and period. Doctors are sure that in the event that an early menopause occurs, in no case can one simply rely on the youth of one's body and patiently wait for it to cope on its own. The process of hormonal adjustment is not an easy procedure. Against the background of it, it is extremely important to support your body from the outside.

The age from thirty-five to forty-five years is the childbearing period and thirty-eight percent of pregnancies fall on it. For this reason, the appearance of menopause at such a moment can be a psychological blow for many. As a result of its appearance, a number of unpleasant symptoms are formed, and, in addition, diseases. In this regard, understanding the danger of menopause for the female body, doctors resort to the use of Femoston 2/10. There are reviews on this.

Doctors write that, in comparison with herbal preparations and dietary supplements, including, the drug is able to actually have an effective effect, fully performing the functions of hormones that are in short supply. According to doctors, in eighty-five percent of cases of treatment with this drug, the menstrual cycle in women returned to normal, and ovulation also occurred on time, thanks to which the patients managed to become pregnant. What other reviews do Femoston 2/10 doctors have?

When removing the ovaries

The effectiveness and efficiency of the drug is noted by doctors in relation to the removal of the ovaries. Due to the replenishment of the supply of necessary hormones, this remedy allows the female body to comfortably move on to the final stage of reproductive functions, getting rid of certain unpleasant manifestations of such a process.

standard menopause

Femoston 2/10 is very often prescribed by doctors against the background of a standard menopause. The drug is prescribed if there is no menstruation for more than six months, that is, immediately on the threshold before the onset of menopause. Doctors note that it is at this time that the symptoms manifest themselves most strongly. In particular, the sexual organs begin to slowly atrophy, causing pain. The resulting hot flashes can cause discomfort up to thirty times a day. Especially often this whole process is accompanied by irritability, and, in addition, neurosis and malaise, which overcomes women at every step. According to doctors, Femoston 2/10 helps to cope with these symptoms. And they disappear after the first week of using this drug.

Postmenopause

Against the background of postmenopause, the drug is prescribed by doctors mainly as a preventive measure for various diseases, especially bone insufficiency, as well as ailments such as osteochondrosis, jumps in blood pressure and heart disease. Reviews of women about "Femoston 2/10" are presented below.

At a concentration of 1 and 5 mg, respectively. As auxiliary components are used: lactose in the form of monohydrate, methyl hydroxypropyl cellulose, anhydrous colloidal silicon dioxide, corn starch, macrogol 400, magnesium stearate, iron dyes (yellow oxide E172 and red E172), titanium dioxide (E171), Opadry orange.

Tablets have the same composition. Femoston Conti 1/5.

IN tablets Femoston 1/10 white color is used as an active component estradiol . The concentration of the substance is 1 mg / tab. Each gray tablet Femoston 1/10 estradiol And dydrogesterone contained in a ratio of 1:10 (1 mg estradiol for 10 mg dydrogesterone ).

In pink tablets Femoston 2/10 contains as an active ingredient estradiol at a concentration of 2 mg / tab. In light yellow tablets estradiol And dydrogesterone contained in a ratio of 2:10 (2 mg estradiol for 10 mg dydrogesterone ). Auxiliary components: lactose in the form of monohydrate, hypromellose, magnesium stearate, corn starch, colloidal silicon dioxide, Opadry (respectively, white, gray, pink and yellow).

Release form

The dosage form of the drug is film-coated round, biconvex tablets with a diameter of 0.7 cm. The tablets differ in color depending on the concentration of the active substance / substances, each of them has the marking “379” on one side.

On tablets Femoston 1/5 the letter “S” is engraved on the other side. Tablets are available in calendar packs of 28 pieces.

Tablets with a higher concentration of active substances are packaged in calendar packages as follows:

• 14 white tablets 1 mg + 14 gray tablets 1 mg + 10 mg (Femoston 1/10);
• 14 pink tablets 2 mg + 14 light yellow tablets 2 mg + 10 mg (Femoston 2/10).

pharmachologic effect

Anticlimacteric estrogen-progestogen for “calendar” (sequential) reception.

Pharmacodynamics and pharmacokinetics

Femoston is combined hormonal drug used to eliminate symptoms of estrogen deficiency and treatment of DMK - dysfunctional uterine bleeding .

• hyperhidrosis;
• tides;
• involution of the mucous membranes and skin, and especially the mucous membranes of the urogenital tract (in particular, the vaginal mucosa, due to which the woman begins to experience discomfort during sexual intercourse);
• increased nervous excitability;
• headaches and dizziness;
• sleep disorders;
• loss of bone mass or (especially if certain risk factors are noted, long-term treatment glucocorticosteroids in the recent past, early onset menopause , asthenic body type, smoking, etc.).

Also estradiol helps to reduce concentration general and low-density LP, while simultaneously increasing the concentration of high-density LP.

Action gestagenic component of the drug dydrogesterone - is aimed at stimulating the onset of the secretory phase of the endometrial cycle, and also reduces the risk carcinogenesis And endometrial hyperplasia, associated with influence estrogen .

Dydrogesterone does not provide androgenic estrogenic , glucocorticosteroid or anabolic action . For maximum preventive effect (HRT), treatment is recommended to start as soon as possible after the onset of menopause .

After taking p / os, estradiol is easily absorbed. The biotransformation of a substance is carried out in liver , the products are estrone And estrone as sulfate . Estradiol And estrone glucuronides eliminated from the body mainly in the urine.

Dydrogesterone also rapidly absorbed from digestive tract after receiving p/os. The substance is completely biotransformable, the main product metabolism - 20-dihydrodydrogesterone. breeding metabolites carried out mainly with urine.

Half-life dydrogesterone - from 5 to 7 hours, its main metabolite - from 14 to 17 hours, the substances are completely excreted after 72 hours.

Indications for use

The use of Femoston is indicated for hormone replacement therapy to eliminate the phenomena caused estrogen deficiency in women in postmenopausal period .

The medicine is prescribed no earlier than six months after the last menstrual bleeding.

Prophylactic administration of the drug is advisable to prevent the development osteoporosis after the onset menopause . The drug is prescribed to women who have an increased risk of fractures and who are contraindicated in the use of other drugs intended to prevent bone loss.

Contraindications

The drug is not prescribed:

• women who have been diagnosed in the past malignant estrogen- or progestogen-dependent tumors , as well as if there are suspicions of these diseases;
• patients diagnosed or suspected;
• at vaginal bleeding unspecified nature of origin;
• at untreated hyperplasia (pathological growth) endometrium ;
• with a currently detected or noted in the anamnesis venous thromboembolism (including but not limited to DVT and PE);
• if the patient has some thrombophilic disorders (including when thrombophilia associated with deficiency antithrombin , coagulation protein C or its cofactor protein S );
• at thromboembolic diseases of the arteries , including including or (both in the active stage and in cases where the disease has been transferred in the recent past);
• with active disease liver , and also, if the patient has not recovered after the illness biochemical parameters of the liver ;
• at porphyrin disease ;
• if known about individual intolerance estradiol , dydrogesterone or auxiliary components of Femoston;
• children and adolescents under 18;
• during pregnancy (both established and if pregnancy is suspected);
• during lactation.

Side effects

The category of side effects that often occur in connection with the use of Femoston include: pain (headaches, in the abdomen, in the pelvic area), nausea, migraine attacks, flatulence, leg cramps, increased sensitivity and / or soreness of the mammary glands, metrorrhagia, the appearance of bloody vaginal bleeding after the onset of menopause, asthenia, weight loss/increase.

With a frequency of 1/1000-1/100 in the course of clinical studies, phenomena such as:

• vaginal candidiasis ;
• depression;
• size increase uterine fibroids ;
• change libido ;
• increased nervousness;
• DVT, PE;
• dizziness;
• disease gallbladder ;
• backache;
• allergic reactions on the skin, accompanied by itching, rashes;
• ulcers on the cervix ;
• the appearance of cervical discharge;
• peripheral edema.

In rare cases (with a frequency of 1/10000-1/1000), drug therapy was accompanied by:

• intolerance to contact lenses;
• functional disorders liver , which often appear as asthenia , malaise, abdominal pain, jaundice ;
• an increase in the curvature of the cornea of ​​\u200b\u200bthe eye;
• enlargement of the mammary glands;
• premenstrual tension syndrome.

In isolated cases, the drug can provoke the development chorea , hemolytic anemia, stroke, myocardial infarction, vascular purpura, vomiting, erythema nodosum or polymorphism, melanopathy, or chloasma(often persisting even after discontinuation of the drug), angioedema , hypersensitivity reactions, worsening porphyrin disease .

In addition, in connection with the treatment estrogen-progestogen drugs women sometimes develop neoplasms (benign, malignant or unknown etiology), increase in size progestogen-dependent tumors , appear fibrocystic lesions of the mammary glands , the concentration increases triglycerides in and concentration thyroid hormones ; develop arterial hypertension , acute blockage arteries , peripheral vascular disease, (against the background of pre-existing hypertriglyceridermia), cystitis-like syndrome , urinary incontinence; aggravated, symptoms appear.

Femoston tablets: instructions for use

Most often, Femoston is taken on days strictly defined by the attending physician, taking into account the characteristics of a particular menstrual cycle . In the absence of menstrual bleeding, the tablets should be taken on the expected days when they should have started. At amenorrhea observed during the year, the drug can be started at any time.

Instructions for use Femoston 1/5

The drug is intended for continuous use: tablets are taken p / os, one per day (optimally - at the same time), without being tied to the time of eating. The duration of one cycle is 4 full weeks (1 package No. 28 is designed for one cycle). There is no need to take a break between cycles.

For relief of symptoms menopause the drug is started with the minimum effective dose. Treatment begins with the appointment of Femoston 1/5. Considering the timing menopause, the severity of the symptoms accompanying it and the effectiveness of therapy in the dosing regimen may be adjusted.

If necessary, the transition from another having in its composition estrogen And progestogenic components of the drug for sequential (or cyclic) administration, the patient should complete a full four-week course and only after that proceed to treatment with Femoston 1/5 (reception can be started on any day). There is no break between cycles.

The scheme of application of the drug Femoston 1/5 Conti is similar to that described above.

Instructions for use Femoston 1/10

Femoston 1/10 tablets should be drunk regardless of the meal time. Estrogen as part of the drug is intended for continuous daily intake during the first two weeks of the cycle.

Progestogenic the component is added in the last 14 days of each four-week course.

Treatment begins with taking white tablets according to the scheme: 1 tablet 1 time per day (at the same time) during the first 2 weeks of the cycle. Further, following the instructions on the package, they begin to take gray tablets (also, one per day).

There is no need to take breaks between 28-day cycles.

Sequential combined HRT begins with the appointment of Femoston 1/10, in the future, if necessary, the dose is adjusted taking into account the clinical results of therapy.

To switch from a similar drug, you should complete the full cycle of treatment and only then start taking Femoston 1/10 tablets. You can do this on any day.

Instructions for use Femoston 2/10

estrogen component of the drug should be taken continuously, progestogenic the component is administered from the 15th day of the 28-day cycle.

This means that in the first 2 weeks of the cycle, the patient should take 1 pink tablet per day, and, starting from the 15th day, following the instructions on the drug package, switch to taking yellow tablets.

Usually starting dose estradiol - 1 mg, therefore, sequential combined HRT is started with Femoston 1/10 and, if necessary, they eventually switch to a higher dose.

The transition from other drugs to Femoston 2/10 is carried out only at the end of a full four-week cycle (on any day).

How to take Femoston in case of missing the next dose?

If a woman misses the next dose of the drug, the pill should be taken as soon as possible. If more than 12 hours have passed after the pass, then the course is continued by taking the next tablet from the package (you do not need to drink the missed one).

Taking a double dose to make up for a missed dose is not advisable, as it is associated with an increased risk of breakthrough bleeding and the appearance of spotting vaginal discharge.

How to take the drug to patients of different age groups?

There is no sufficient experience in the use of Femoston for the treatment of patients over 65 years of age.

There are no indications for prescribing the drug to children and adolescents.

Overdose

Cases of overdose with Femoston have not been recorded.

AND estrogenic , And progestogenic the components of the tablets are classified as low-toxic substances.

Theoretically, an overdose can provoke an increase in the severity of such side effects as: nausea, vomiting, dizziness, drowsiness.

It is unlikely that any specific symptomatic treatment may be required due to an overdose (including overdose in children).

Interaction

Femoston drug interaction studies have not been conducted.

However, it is known that some drugs may affect the effectiveness estrogen And progesterone .

For example, anticonvulsants (eg. phenytoin or ) and antimicrobial (including nevirapine , or efavirenz ) drugs enhance the biotransformation of these substances, which is associated with their ability to induce those involved in metabolism medicinal product enzymes of the cytochrome P450 system .

Ritonavir And nelvinavir , which are potent inhibitors of CYP isoenzymes 3A4, A5 and A7, in combination with steroid hormones , contribute to the activation of these cytochromes.

Phytopreparations , which are based on St. John's wort (Hypericum) perforatum, can stimulate biotransformation estrogen And progestogens due to the ability to act on the CYP 3A4 isoenzyme.

There is evidence that more actively flowing estrogen metabolism And progestogens provokes a decrease in the clinical effectiveness of these substances and affects the profile of uterine bleeding.

In its turn estrogens can disrupt the process of biotransformation of other substances due to competitive suppression cytochromes of the P450 system , which take part in the processes of biotransformation of the active substances of drugs.

This should be kept in mind when assigning estrogens in combination with drugs with a narrow therapeutic index, including fentanyl , , theophylline , cyclosporine .

Such combinations can cause an increase in the plasma concentration of these substances to a toxic level. Therefore, it may be necessary to carefully monitor the drug over an extended period of time, as well as dose reduction. cyclosporine, tacrolimus, theophylline and fentanyl .

Terms of sale

On prescription.

Storage conditions

The optimal storage conditions for Femoston tablets are to maintain a temperature of no more than 30 degrees Celsius. The drug must be stored in its original packaging. Keep away from children.

Best before date

The drug is suitable for use within 36 months after the date of issue.

special instructions

The drug is recommended to be used only in the presence of symptoms that have an adverse effect on the quality of life. Treatment is continued until the benefit of using the drug outweighs the risk of side effects.

Analogues

Coincidence in the ATX code of the 4th level:

The generic (structural analogue) of Femoston ⅕ is Femoston Conti 1/5.

Drugs with a similar mechanism of action:,.

Klimonorm or Femoston - which is better?

Deciding which drug from the combination group estrogen-progestin drugs you should choose whether the doctor takes it based on the data received from the patient about the period of age-related hormonal changes.

It is believed that the drug Klimonorm gestagenic the component is present in the most optimal concentration, which allows you to effectively control the cycle and provides the necessary level protection of the endometrium from the hyperplastic effect of estrogen .

At the same time, it is possible to maintain favorable effects due to the influence of estrogen on the state cardiovascular system and lipid metabolism . In addition, contained in Klimonorme potentiates action estradiol for the treatment and prevention osteoporosis .

Another important feature levonorgestrel is its almost 100% bioavailability, thanks to which it is possible to maintain the stability of the effects of the drug.

Moreover, the severity of the effects remains unchanged regardless of the woman’s diet, whether she has digestive tract diseases , as well as activities hepatic system , which plays a key role in the processes first pass metabolism of xenobiotics .

Bioavailability dydrogesterone , which is part of Femoston, is 28%, and therefore its effects are subject to fluctuations (both inter- and inter-individual).

Angelique or Femoston - which is better?

Experts believe that there is no particular difference between these funds. The main difference between the drug and Femoston is that, as gestagenic component it includes at a concentration of 2 mg / tab.

Use with alcohol

In the manufacturer's instructions, the interaction of Femoston with alcohol is not described.

During pregnancy

The use of Femoston is contraindicated if it is known for sure that the woman is pregnant, and also, if there is reason to assume pregnancy. It is also contraindicated to take the drug for women who are breastfeeding.

In some cases, the drug is prescribed during pregnancy planning. The indications are:

• deficiency conditions. estrogen and manifested by insufficiency of the first phase (that is, conditions in which, by the end of the first (follicular) phase menstrual cycle the thickness of the endometrial layer does not exceed 7-8 mm);
• infertility caused by hormonal imbalance.

Too thin endometrium can cause a violation of the luteal phase and, as a result, the fact that a woman cannot become pregnant.

Concentration estradiol in tablets intended for use during the first 2 weeks of the cycle, such that the drug, unlike contraceptives, does not suppress ovulation , while modeling the first phase menstrual cycle and stimulates cell division and growth.

Taking pills containing estradiol added dydrogesterone, in turn, provides secretory transformation inner layer of the uterus necessary for normal implantation eggs in case of fertilization and pregnancy. Thus, Femoston 2/10 allows you to normalize the disturbed menstrual cycle .

Femoston 2/10 when planning pregnancy is taken from the first day of the menstrual cycle, one tablet per day for 4 full weeks. Do not stop treatment before the entire package is finished, as this can provoke a hormonal imbalance, manifested by breakthrough bleeding of varying degrees of intensity and leaving no chance of pregnancy.

Women who, when planning pregnancy, take Femoston should further strengthen the luteal (second) phase of the cycle, therefore, from the 14th day of treatment, the patient is prescribed to take the drug in combination with (or its equivalent).

As gestagenic component in Duphastone present dydrogesterone , and this allows you to enhance the positive effect of therapy on the female body and condition endometrium .

Duphaston take one tablet twice a day for a full two weeks.

Can I get pregnant while taking the drug?

Pregnancy that occurred during the period of Femoston use is an exception. As a rule, the chances of getting pregnant after taking the drug for several cycles are considered more realistic, and this usually occurs after stopping treatment.

In extremely rare cases, it is possible to use the remedy against the background of an already completed pregnancy, when a woman needs support endometrium . However, such a decision can only be made by a qualified specialist.

Reviews about Femoston

A considerable number of reviews about Femoston 1/5 Conti have been left on the forums. Like reviews of Femoston 2/10 or 1/10, they are quite contradictory. As a rule, in the reviews, women describe the experience of using the remedy for menopause or when planning pregnancy .

Those who were satisfied with the treatment, as the advantages of the drug, note that it is quite well tolerated and rarely causes side effects, quickly normalizes the condition, stopping the unpleasant symptoms of the onset menopause , and improves overall well-being, has a positive effect on the condition of the skin, restores the cycle in case of violation, and is convenient to use.

Negative reviews are associated with the occurrence of unwanted side effects (depression, rash, excess weight, edema, decreased activity, joint pain, etc.), as well as the lack of the expected effect.

Referring to the doctors' reviews of Femoston 1/10, 2/10 or 1/5, which are based on the results of clinical studies, we can conclude that the drug is a highly effective tool for the treatment and prevention of conditions that have developed due to premature exhaustion ovaries .

At the same time, all patients showed good tolerability of the tablets. Studies have established a pronounced positive effect of therapy on the general well-being of women and, in particular, on blood lipid profile .

Against the background of the treatment, a significant increase in the indicator of maximum oxygen consumption and an increase in dydrogesterone bone-protective estrogen Femoston component.

Thus, doctors confirm the need for early initiation and differentiated choice of hormone replacement therapy in women with "off" ovarian function .

Femoston price

Price Femoston 1/5 in Russian pharmacies from 870 rubles. Buy Femoston Conti 1/5 can be an average of 900 rubles. Price Femoston 2/10— from 790, Femoston 1/10- from 795 rubles.

Registration number: P N011361/02-141013
Trade name of the drug: Femoston® 2/10
INN or grouping name: Dydrogesterone + Estradiol &
Dosage form: film-coated tablets
Compound:
Active substance: estradiol hemihydrate - 2.06 mg (in terms of estradiol - 2.0 mg).
Excipients: lactose monohydrate - 118.2 mg; hypromellose - 2.8 mg; corn starch - 14.9 mg; colloidal silicon dioxide - 1.4 mg; magnesium stearate - 0.7 mg.
Film sheath: Opadry OY-6957 pink (hypromellose - 2.5056 mg, talc - 0.6 mg, titanium dioxide (E171) - 0.6 mg, macrogol 400 - 0.248 mg, iron oxide red - 0.04632 mg, iron oxide black - 0.00004 mg, yellow iron oxide - 0.00004 mg) - 4.0 mg.

Active substances: estradiol hemihydrate - 2.06 mg in terms of estradiol - 2.0 mg and dydrogesterone 10 mg.
Excipients: lactose monohydrate - 109.4 mg; hypromellose - 2.8 mg; corn starch - 13.7 mg; colloidal silicon dioxide - 1.4 mg; magnesium stearate - 0.7 mg.
Film sheath: Opadry OY-02V22764 yellow (hypromellose - 2.5 mg, talc - 0.6244 mg, titanium dioxide (E 171) - 0.6116 mg, macrogol 400 - 0.25 mg, iron oxide yellow - 0.014 mg) - 4, 0 mg.

Description
Estradiol 2 mg tablets:
Pink, round, biconvex, film-coated tablets, debossed with "379" on one side of the tablet.

Tablets 2 mg estradiol/10 mg dydrogesterone:
Round, biconvex, light yellow film-coated tablets, debossed with "379" on one side of the tablet.
Type of tablet on a break: white rough surface.

Pharmacotherapeutic group: combined anti-menopausal agent (estrogen + gestagen).

ATX code: G03FB08.

Pharmacological properties

Estradiol, which is part of Femoston®2/10, is identical to endogenous human estradiol, which is the most active estrogen.
Estradiol compensates for the deficiency of estrogen in the female body in menopausal women and reduces menopausal symptoms during the first weeks of treatment.
Hormone replacement therapy (HRT) with Femoston® 2/10 prevents bone loss in the postmenopausal period or after oophorectomy.
Dydrogesterone is a progestogen that is effective when taken orally and has activity similar to that of parenterally administered progesterone.
When conducting HRT, the inclusion of dydrogesterone provides a complete secretory transformation of the endometrium, thereby reducing the increased risk of endometrial hyperplasia under the action of estrogens.

Estradiol

The absorption of estradiol depends on the particle size, micronized estradiol is easily absorbed from the gastrointestinal tract.

Estrogen can be found in both bound and free states. About 98-99% of a dose of estradiol binds to plasma proteins, of which 30-52% to albumin and about 46-69% to sex hormone-binding globulin (SHBG).

Estradiol is metabolized in the liver to estrone and estrone sulfate, which have estrogenic activity. Estrone sulfate may undergo enterohepatic recirculation.

Estrone and estradiol are excreted in a state conjugated with glucuronic acid, mainly by the kidneys. The half-life (T1 / 2) is 10-16 hours.
Estrogens pass into breast milk.

With daily intake of the drug Femoston® 2/10, the concentration of estradiol in the blood plasma reaches a constant value after about 5 days.
Dydrogesterone

After oral administration, it is rapidly absorbed and completely metabolized. The values ​​of the time of onset of the maximum concentration (Tmax) for dydrogesterone vary from 30 minutes to 2.5 hours. The bioavailability of dydrogesterone is 28%.

More than 90% of dydrogesterone and DHD bind to plasma proteins.

The main metabolite of dydrogesterone is 20α-dihydrodydrogesterone (DHD). The maximum concentration of DHD in the blood plasma is reached approximately 1.5 hours after taking the drug. The concentration of DHD in blood plasma significantly exceeds the initial concentration of dydrogesterone, the ratio of the area under the concentration-time curve (AUC) and the maximum concentration (Cmax) of DHD to dydrogesterone is about 40 and 25, respectively. The half-life for dydrogesterone is 5-7 hours, for DHD 14-17 hours.
A common feature of all dydrogesterone metabolites is the preservation of the 4,6-dien-3-one configuration of the parent substance and the absence of 17α-hydroxylation, which leads to the absence of estrogenic and androgenic activity.

Completely dydrogesterone is excreted after 72 hours. On average, 63% of the dose taken is excreted by the kidneys. The total plasma clearance is 6.4 l / min. DHD is determined in the urine mainly as a conjugate of glucuronic acid.

Comparison of the kinetics of single and multiple doses shows that the pharmacokinetic properties of dydrogesterone and DHD do not change when taking multiple doses.
Steady-state concentration of dydrogesterone was reached 3 days after treatment.

Indications for use

Hormone replacement therapy for disorders caused by estrogen deficiency in perimenopausal women (not earlier than 6 months after the last menstruation) or in postmenopausal women.
Prevention of postmenopausal osteoporosis in women at high risk of fractures with intolerance or contraindications to the use of other drugs.

Contraindications

Pregnancy and the period of breastfeeding.
Diagnosed or suspected breast cancer.
Diagnosed or suspected estrogen-dependent malignant neoplasms (for example, endometrial cancer).
Diagnosed or suspected progestogen-dependent neoplasms (eg, meningioma).
Bleeding from the vagina of unknown etiology.
Untreated endometrial hyperplasia.
Thrombosis (arterial and venous) and thromboembolism at present or in history (including thrombosis, deep vein thrombosis; pulmonary embolism, myocardial infarction, ischemic or hemorrhagic cerebrovascular disorders).
Multiple or prominent factors in arterial or venous thrombosis associated with a congenital or acquired predisposition, eg, protein C deficiency, protein S deficiency, antithrombin III deficiency, presence of antibodies to phospholipids (anti-cardiolipin antibodies, lupus anticoagulant), angina pectoris, prolonged immobilization, severe forms obesity (body mass index more than 30 kg / m 2), cerebrovascular disease or coronary arteries, transient ischemic attacks, complicated lesions of the valvular apparatus of the heart, atrial fibrillation.
Current or past acute or chronic liver disease (before normalization of liver function tests), including malignant liver tumors.
Porfiry.
Hypersensitivity to the components of the drug.
Galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
Taking the drug Femoston® 2/10 should be discontinued if contraindications are identified and / or if the following conditions occur:
jaundice and / or abnormal liver function;
uncontrolled arterial hypertension;
migraine-like headache that first appeared against the background of the use of drugs for HRT.

Carefully HRT is prescribed to women if they have been diagnosed with or have been diagnosed with:
Uterine leiomyoma, endometriosis.
The presence of risk factors for the occurrence of estrogen-dependent tumors (for example, relatives of the 1st degree of relatives with breast cancer).
Arterial hypertension.
Benign tumors of the liver.
Diabetes mellitus, both in the presence of vascular complications, and in the absence of them.
cholelithiasis.
Migraine or severe headache.
Systemic lupus erythematosus.
History of endometrial hyperplasia.
Epilepsy.
Bronchial asthma.
Otosclerosis.

Use during pregnancy and during breastfeeding

The drug is contraindicated during pregnancy and during breastfeeding.
If pregnancy occurs during treatment with Femoston® 2/10, therapy should be stopped immediately.

Dosage and administration

The drug is taken orally daily, continuously, 1 tablet per day (preferably at the same time of day), regardless of the meal.
Each package is designed for a 28-day intake of the drug. In the first 14 days, take 1 pink tablet daily (from half of the package with an arrow marked with the number "1") containing 2 mg of estradiol, and for the remaining 14 days - 1 light yellow tablet daily (from half of the package with an arrow, marked with the number "2"), containing 2 mg of estradiol and 10 mg of dydrogesterone.
Usually, treatment should begin with the drug Femoston® 1/10. Depending on the clinical efficacy, the doses of active substances can be adjusted according to individual needs. If complaints related to estrogen deficiency persist, the dosage can be increased using Femoston® 2/10.
Patients making the transition from another continuous sequential or cyclic regimen of the drug should complete the current cycle, and then switch to Femoston® 2/10. Patients making the transition from a continuous combination regimen of therapy can start taking Femoston® 2/10 on any day.
If the patient misses a tablet, it must be taken within 12 hours after the usual time of taking; otherwise, the missed tablet should not be taken and the next day the tablet should be taken at the usual time. Missing the drug may increase the likelihood of "breakthrough" uterine bleeding.

Side effect

In clinical studies, in patients treated with estradiol / dydrogesterone combination therapy, the most common were: headache, abdominal pain, breast tension / tenderness and back pain.
In clinical studies (n=4929), the following adverse effects were observed with the frequency of development indicated below (number of reported cases / number of patients):
Often- from 1 to 10 cases;
often- from 1 in 100 to 1 in 10 cases;
infrequently- from 1 in 1000 to 1 in 100 cases;
rarely- from 1 in 10,000 to 1 in 1,000 cases;
very rarely- less than 1 in 10,000 cases.
From the nervous system:
Very often - a headache.
Often - migraine, dizziness.
Mental disorders:
Often - depression, nervousness.
Infrequently - a change in libido.
From the side of the cardiovascular system:
Infrequently - venous thromboembolism, increased blood pressure.
Rarely - myocardial infarction.
From the gastrointestinal tract:
Very often - pain in the abdomen.
Often - nausea, vomiting, flatulence.
From the hepatobiliary system:
Infrequently - diseases of the gallbladder, impaired liver function, sometimes in combination with jaundice, asthenia, malaise, abdominal pain.
From the reproductive system and mammary glands:
Very often - tension / soreness of the mammary glands.
Often - "spotting" spotting in postmenopause, metrorrhagia, profuse menstrual-like bleeding, scanty or no menstrual-like bleeding, acyclic spotting, painful menstrual-like bleeding, pain in the lower abdomen, changes in vaginal secretion, vaginal candidiasis.
Infrequently - an increase in the size of leiomyomas, an increase in the mammary glands, premenstrual-like syndrome.
From the immune system:
Infrequently - hypersensitivity to the drug or any of the components of the drug.
From the skeletal muscles and connective tissue:
Very often - pain in the back (lower back).
From the side of the skin and subcutaneous fat:
Often - allergic reactions such as hives, skin rash and itching.
Rarely - vascular purpura, angioedema.
Infectious diseases:
Infrequently - cystitis.
General disorders:
Often - asthenic conditions (weakness, malaise, fatigue), peripheral edema.
Others:
Often - an increase in body weight.
Infrequently - weight loss.
Other side effects caused by estrogen and progestogen combination treatment (including estradiol/dydrogesterone):
Benign, malignant, and unspecified neoplasms (eg, endometrial cancer, ovarian cancer, meningioma).
From the hemopoietic system: hemolytic anemia.
From the immune system: systemic lupus erythematosus.
From the side of the nervous system: the risk of developing dementia in women starting the use of drugs for HRT, over the age of 65, chorea, provoking epileptic seizures.
On the part of the organs of vision: intolerance to contact lenses, an increase in the curvature of the cornea.
On the part of the skin and subcutaneous fat: chloasma and / or melasma, which may persist after discontinuation of the drug, erythema multiforme, erythema nodosum.
From the skeletal muscles and connective tissue: cramps in the muscles of the lower extremities.
From the side of the cardiovascular system: arterial thromboembolism.
From the genitourinary system: urinary incontinence.
From the reproductive system and mammary glands: fibrocystic mastopathy, cervical erosion.
Congenital and hereditary disorders: worsening of the course of concomitant porphyria.
Metabolic disorders: hypertriglyceridemia.
Gastrointestinal disorders: pancreatitis (in patients with hypertriglyceridemia).
Diagnostic tests: elevated levels of thyroid hormones.

Overdose

Estradiol and dydrogesterone are substances with low toxicity.
In case of an overdose, symptoms such as nausea, vomiting, breast tension, dizziness, abdominal pain, drowsiness/weakness and withdrawal bleeding may develop.
Treatment is symptomatic.

Interaction with other drugs

Metabolism of estrogens and progestogens can be increased while taking drugs-inducers of microsomal liver enzymes (P450 2B6, 3A4, 3A5, 3A7): anticonvulsants (phenobarbital, carbamazepine, phenytoin) and antimicrobials (rifampicin, rifabutin, nevirapine, efavirenz).
Herbal preparations containing St. John's wort (Hypericum perforatum) may increase the metabolism of estrogens and progestogens through CYP 450 3A4.
Ritonavir and nelfinavir, although they are known as strong inhibitors of CYP 450 3A4, A5, A7, when used simultaneously with sex hormones, can increase their metabolism.
An increase in the metabolism of estrogens and progestogens can be clinically manifested by a decrease in the effect of the drug and a change in the intensity of bleeding from the vagina.

Estrogens may interfere with the metabolism of other drugs through competitive binding to enzymes (CYP 450) involved in their breakdown. This should be considered for drugs with a narrow therapeutic range, such as tacrolimus and cyclosporine A (CYP 450 3A4, 3A3), fentanyl (CYP 450 3A4) and theophylline (CYP 450 1A2), as this type of interaction can lead to an increase in concentration in blood plasma of the above drugs to toxic levels. In this regard, careful monitoring of drug intake over a long period of time and possibly a reduction in the dose of tacrolimus, fentanyl, cyclosporine A and theophylline may be required.
Interaction studies with other medicinal products have not been conducted.

special instructions

The drug is prescribed only in the presence of symptoms that adversely affect the quality of life. Therapy should be continued as long as the benefit of taking the drug outweighs the risk of side effects. The experience of using the drug in women over 65 years of age is limited.
medical examination
Before prescribing or resuming therapy with Femoston® 2/10, it is necessary to collect a complete medical and family history and conduct a general and gynecological examination (including the mammary glands) of the patient in order to identify possible contraindications and conditions requiring precautions. During treatment with Femoston® 2/10, it is recommended to conduct periodic examinations, the frequency and nature of which is determined individually, but not less than 1 time in 6 months.
It is advisable to conduct mammography for additional examination of the mammary glands. Women should be informed about those possible changes in the mammary glands that need to be reported to the attending physician.
The use of estrogens may affect the results of the following laboratory tests: glucose tolerance, thyroid and liver function tests.
endometrial hyperplasia
The risk of endometrial hyperplasia and cancer when patients use only estrogens depends on the dose and duration of treatment and increases from 2 to 12 times compared with no treatment; the risk may remain elevated for up to 10 years after discontinuation of therapy.
Cyclic progestogen (for at least 12 days of a 28-day cycle) or continuous combined HRT in uterine preserved women may prevent estrogen-enhanced risk of endometrial hyperplasia and cancer.
For the purpose of timely diagnosis, it is advisable to conduct an ultrasound (US) screening, if necessary, a histological (cytological) study.
Bloody discharge from the vagina
In the first months of treatment with the drug, "breakthrough" bleeding and / or scanty spotting from the vagina may occur. If such bleeding occurs some time after the start of therapy or continues after discontinuation of treatment, their cause should be determined. An endometrial biopsy may be performed to rule out malignancy.
Venous thromboembolism
HRT is associated with a 1.3-3-fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. This phenomenon is most likely during the first year of HRT.
In the presence of thromboembolic complications in relatives of the 1st degree of kinship at a young age, as well as in a history of habitual miscarriage, it is necessary to conduct a study of hemostasis. If the patient is taking anticoagulants, it is necessary to carefully consider the appointment of the drug Femoston® 2/10 in terms of the benefit / risk ratio. Femoston® 2/10 is not prescribed until a thorough assessment of the factors for the possible development of thromboembolism or the start of anticoagulant therapy is completed.
If a family member has a thrombophilic condition and / or if the defect is serious or severe (for example, antithrombin III, protein S or C deficiency, as well as a combination of defects), Femoston® 2/10 is contraindicated.
Since patients with diagnosed thrombophilic conditions have an increased risk of developing venous thromboembolism, Femoston® 2/10, which increases this risk, is contraindicated.
In most cases, risk factors for VTE include estrogen use, older age, major surgery, prolonged immobilization, obesity (body mass index > 30 kg/m2), pregnancy or the postpartum period, systemic lupus erythematosus, and cancer. There is no consensus on the possible role of varicose veins in the development of VTE.
Preventive measures should be considered to prevent post-surgical VTE in all postoperative patients.
In case of prolonged immobilization after surgery, it is recommended to stop taking Femoston® 2/10 4-6 weeks before, and treatment should not be resumed until the woman's mobility is fully restored.
If VTE develops after the start of therapy, then the drug should be discontinued, and patients should be informed that they should immediately contact their doctor if they experience any potentially thromboembolic symptom (for example, tenderness or swelling of the lower extremities, sudden pain chest, shortness of breath).
Breast cancer and ovarian cancer
In women who received long-term HRT using only estrogens or the estrogen-progestogen complex, the frequency of diagnosing breast cancer increases, which returns to baseline within 5 years after stopping therapy.
The increase in risk depends on the duration of HRT use. In women taking combined estrogen-progestogen HRT for more than 5 years, the risk of developing breast cancer may increase up to 2 times.
Against the background of taking drugs for HRT, there may be an increase in the density of breast tissue during mammography, which can make it difficult to diagnose breast cancer.
Ovarian cancer is much less common than breast cancer. Long-term use (at least 5-10 years) of estrogen monotherapy with HRT is associated with a slight increase in the risk of developing ovarian cancer. Data from several studies, including the WHI, indicate that long-term combined HRT may increase the risk of developing this pathology to the same or somewhat lesser extent.
Ischemic stroke risk
Combination therapy with estrogen and progestogen or estrogen alone is associated with a 1.5-fold increased relative risk of ischemic stroke. The risk of hemorrhagic stroke does not increase with HRT.
The relative risk does not depend on age or duration of therapy, however, the initial risk is highly dependent on age, so the overall risk of stroke in women receiving HRT will increase with age.
Ischemic heart disease (CHD)
The relative risk of coronary artery disease during the use of combined HRT with estrogen + progestogen slightly increases. Due to the fact that the absolute risk of coronary artery disease is highly dependent on age, the number of additional cases of coronary artery disease due to the use of combined HRT in healthy premenopausal women is very small, but it increases with age.
Other states
Estrogens can cause fluid retention, which can adversely affect the condition of patients with impaired renal and cardiac function.
In women with hypertriglyceridemia while taking drugs for HRT, in very rare cases, the concentration of triglycerides in the blood plasma can significantly increase, which contributes to the development of pancreatitis.
Estrogens increase the concentration of thyroid-binding globulin, which leads to an overall increase in the concentration of circulating thyroid hormones (the concentrations of free hormones T3 (triiodothyronine) and T4 (thyroxine) usually do not change). Plasma concentrations of other binding proteins (transcortin, sex hormone-binding globulin) may also increase, leading to an increase in the concentration of circulating glucocorticosteroids and sex hormones. The concentrations of free or biologically active hormones do not change. It is possible to increase the concentration of other plasma proteins (angiotensinogen / renin systems, α-1-antitrypsin, ceruloplasmin).
The use of HRT does not improve cognitive function. There are reports of an increased risk of dementia in women who started using HRT (combined or estrogen-only) after 65 years of age.
Femoston® 2/10 is not a contraceptive.
Influence on the ability to drive vehicles and mechanisms.
Care should be taken when driving vehicles and mechanisms, given the risk of adverse reactions from the nervous system.

Release form
Film-coated tablets.
14 tablets of 2 mg estradiol and 14 tablets of 2 mg estradiol/10 mg dydrogesterone in a PVC/PVDC/Al foil blister.
1, 3 or 10 blisters in a cardboard box along with instructions for use.

Storage conditions
Store at a temperature not exceeding 30°C.
Keep out of the reach of children.

Best before date
3 years.
Do not use after the expiration date.

Terms of dispensing from pharmacies
On prescription.

Registration certificate holder
Abbott Healthcare Products B.V.
S.D. van Houtenlaan 36,
NL-1381 SP Veesp, the Netherlands.

Manufacturer
Abbott Biologicals B.V.
Legal address.
S.D. van Houtenlaan 36, NL-1381 SP Veesp, the Netherlands.
Actual address.
Weerweg 12, 8121 AA Olst, The Netherlands.

Quality claims should be sent to:
Abbott Laboratories LLC
125171, Moscow, Leningrad highway,

Being a mother is the main purpose of a woman. Those women who, for some reason, cannot achieve this cherished goal on their own, are ready to seek medical help from a variety of specialists, undergo a lot of examinations, and endure unpleasant procedures. However, not everything and not always so tragic. There are cases when it is enough for a woman to undergo a course of therapy with some special drug, and here it is - happiness. Pregnancy sets in, and the fair sex lives in anticipation of a miracle - the birth of a new person, her child.

Today, many medicines have been developed that can help a woman become pregnant. One of these is Femoston 2/10. When planning a pregnancy, this medication can provide significant support to the female body and create conditions for the successful fertilization of the egg.

Main components and release form

The drug is a combined hormonal drug intended to eliminate deficiency in a woman's body and to conduct therapeutic therapy for Femoston 2/10 tablets are packaged in packs of 28 pieces, in each blister they are of two colors: pink and light yellow. 14 pink tablets as an active ingredient contain estradiol in a volume of 2 mg each. The remaining 14 tablets (light yellow) contain 2 mg of estradiol and 10 mg of dydrogesterone each.

The auxiliary components are lactose, hypromelase, starch (corn), and colloidal silicon dioxide.

Tablets are biconvex, round, film-coated.

Prescribing a medication

The drug "Femoston 2/10" (reviews, instructions confirm this information) is a good remedy for making up for the lack of estrogen, which is often observed after menopause. This medication is also good for eliminating psycho-emotional and vegetative abnormalities that accompany the onset of menopause. These include hyperhidrosis (excessive sweating), flushing of the skin of the face, increased nervous irritability, deviations in sleep patterns, headaches, dizziness, weight loss (osteoporosis).

There are other indications for the use of Femoston 2/10, and pregnancy in the planning stage is one of them. For his appointment, certain conditions must be met:

1) an insufficient amount of estrogen by the end of the first half of the menstrual cycle will make itself felt by insufficient thickness (no more than 7-8 mm) of the endometrial layer;

2) diagnosed infertility caused by hormonal imbalance in the body.

Medical professionals with the help of this drug seek to solve the problems that prevent a woman from getting pregnant: a thin layer of the endometrium and a lack of estrogen. Dydrogesterone - one of the components of the drug "Femoston 2/10" - when planning a pregnancy, stimulates the uterine mucosa to grow, thicken. This is important in order for the fertilized egg to freely adhere to the wall of the uterus.

In addition, the drug helps the woman's body to restore the regularity of the ovulation process, without which conception and pregnancy are impossible in principle. Although I must say that in the process of taking the pills, ovulation should not occur. This process is resumed after the course of therapy is completed.

Many representatives of the fair sex doubt the effectiveness of the use of the Femoston 2/10 drug. Reviews, pregnancy, which occurred in a considerable number of women after the end of the intake, prove that taking this drug is very justified when planning conception.

For whom is the drug contraindicated?

"Femoston 2/10" when planning pregnancy, not every specialist prescribes. The reason is a large list of contraindications. It should not be taken by women who have been diagnosed or suspected of having estrogen and progesterone dependent cancers.

Do not prescribe the drug to women suffering from vaginal bleeding of unknown origin, who have not cured hyperplasia (pathological growth) of the endometrium. It is unacceptable to use the drug in the presence (or a history of) venous thromboembolism, angina pectoris, myocardial infarction (in the active phase or recently transferred).

It is forbidden to take the drug to patients suffering from liver diseases in the active stage, or if the biochemical parameters of this organ have not yet returned to normal. A contraindication for taking the medication is the presence of a porphyrin disease in the patient (a violation of pigment metabolism due to an increased content of porphyrins in tissues and blood).

Women with individual sensitivity to estradiol and dydrogesterone, as well as the rest of the components of the Femoston 2/10 medication, should not take this drug. Reviews, instructions indicate the negative consequences if the medication is taken during pregnancy. Therefore, you should stop using it even if you only assume an interesting position in yourself. During the lactation period, the remedy is also prohibited. Do not prescribe it to children and adolescents under the age of 18 years.

Possible negative effects from the use of the drug

Most often, the drug can be heard in a negative context due to negative manifestations in the form of headaches, discomfort in the pelvic region and in the abdomen, migraine attacks, nausea, and flatulence. The use of "Femoston 2/10" can cause pain in the mammary glands, increase their sensitivity, provoke the appearance of bloody discharge from the vagina against the background of menopause that has already begun, and significantly affect weight changes (increase or decrease).

Clinical studies have shown that quite often you can hear about side effects in the form of the development of vaginal candidiasis, an increase in the size of the change in libido, increased nervousness or depression. In addition, experts put the development of ulcers on the cervix, the appearance of discharge from the cervical canal in direct dependence on the use of the Femoston 2/10 medication. Reviews of doctors report that against the background of the use of the remedy, cases of peripheral edema, urticaria, skin rashes, dysmenorrhea were recorded.

Quite rarely, but you can hear about such side effects as disorders in the functioning of the liver, premenstrual tension syndrome, a change (usually upwards) in the curvature of the eye cornea, rejection, rejection of contact lenses.

Sometimes it is possible to develop such formidable diseases as stroke, increased susceptibility to myocardial infarction, anemia (hemolytic nature), vascular purpura. There have been cases of increased blood pressure, the development of dyspepsia, pancreatitis, systemic lupus erythematosus, the appearance of signs of dementia (rarely).

Scheme of administration and dosing regimen

Before answering the question of how to drink Femoston 2/10, it should be said that the estrogenic component of the drug is recommended to be taken constantly, and the progestogenic component - from the middle of the menstrual cycle to the end (with a cycle of 28 days, start from day 15). Simply put, in the first half, a woman should take one pink tablet, and from the middle of the cycle, as a rule, from day 15, switch to taking yellow tablets.

Usually, therapy begins with a minimum dose of estradiol, which is 1 mg. Therefore, if combined long-term treatment with the use of this drug is expected, experts prefer to prescribe Femoston 1/10 first. Then, if necessary, the patient is transferred to a higher dose.

It is allowed to start treatment only after a full four-week cycle has been completed.

If for any reason the next tablet was missed, it should be taken immediately. However, if more than 12 hours have passed since the time when the drug is usually taken, it is no longer necessary to take the missed dose. It is not recommended to use a double dose of Femoston 2/10. Similar drugs are basically characterized by the same features of the reception. If you take a double dose, you still won’t be able to make up for the missed one, but the likelihood of bleeding will increase. Also in such cases, the appearance of spotting vaginal discharge is possible.

As for the use of the drug by patients over 65 years of age, it is difficult to say something here, since there is no sufficiently reliable information about the results of such use. As there are no indications to prescribe "Femoston 2/10" (the drug is still hormonal) to children and adolescents.

Similar medicines

If we talk about the structural analogues (generics) of Femoston, then the closest of them is Femoston 1/5 Konti. A similar principle of influence on a woman's body is possessed by Trisequens, Divina, Kliogest, Klimonorm. The final word on the question of how to replace "Femoston 2/10" should remain with the attending physician.

In a positive way, medical workers speak of such an analogue as Klimonorm. The reason is that, according to clinical studies, the progestogen component in this medication is present in the optimal dosage necessary for effective cycle control and ensuring the proper level of protection of the endometrium from the effects of estrogen. In parallel with this, it is possible to maintain the positive effect of estrogen on the state of the cardiovascular system and lipid metabolism processes.

Also, "Femoston 2/10", whose analogues make up a fairly large group, patients are often replaced with the drug "Angelik". Although experts are inclined to believe that there is no particular difference between these medicines. The main difference is that the progestogen component of Angelica is drospirenone at a dosage of 2 mg per tablet.

So what about pregnancy?

If it is known for certain that a woman is pregnant or there is reason to assume such a fact, Femoston 2/10 should be discontinued.

When planning a pregnancy, it can be very effective for the reason that the amount of estradiol in pink tablets recommended for taking in the first half of the cycle does not slow down or suppress the ovulation process, simulates the correct course of the follicular phase and stimulates endometrial cells to divide and grow.

The optimal balance of the two main components for the second half of the cycle is able to ensure (in case of conception) the normal introduction of a fertilized egg into the inner layers of the uterus. Thus, "Femoston 2/10" (reviews of doctors once again confirm this) is a remedy for eliminating deviations of the menstrual cycle.